Merck opens €150 million manufacturing facility in Ireland
Merck opens first climate-neutral manufacturing facility in Ireland
Merck opens first climate-neutral manufacturing facility in Ireland
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
The FDA is beginning rulemaking to close the “adequate provision” loophole
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Subscribe To Our Newsletter & Stay Updated